Ascendia

  MARKET NEWS

selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients With Psoriasis Vulgaris or Psoriatic Arthritis
CARGO Therapeutics Announces $110-Million Private Placement Equity Financing
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism
BriaCell Announces Clinical Supply Agreement With BeiGene for Bria-OTS First in Human Study
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 in Patients With Alzheimer’s Disease
TFF Pharmaceuticals & Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program Into Preclinical Testing

  FEATURED EDITORIAL

  COMPANY PROFILE

Proveris Scientific  is an instrument and laboratory service company that creates today’s most advanced testing solutions for orally inhaled and nasal drug product (OINDP) drug development and manufacturing. As partners to our clients, we: accelerate successful product development, and prevent late-stage development failures, realize significant savings in time and resources by streamlining testing workflows, evaluate the suitability of various OINDP delivery devices and optimize device parameters for maximum efficacy, and optimize testing variables to maintain batch-to-batch reproducibility, simplifying regulatory submissions. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company

Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company

Asahi Kasei Corp. recently announced it will offer the shareholders of Calliditas Therapeutics AB to acquire the shares of the pharmaceutical company Calliditas for the purpose of….

Agios Announces 5-Million Purchase Agreement for Vorasidenib Royalty

Agios Announces $905-Million Purchase Agreement for Vorasidenib Royalty

Agios Pharmaceuticals, Inc. recently announced it has agreed to sell its rights to its 15% royalty on potential US net sales of Servier’s vorasidenib to….

GlycoNex & PrecisemAb Sign Technology Licensing Agreement to Advance Development of Novel Anti-Glycan Antibodies for Cancer Therapy

GlycoNex & PrecisemAb Sign Technology Licensing Agreement to Advance Development of Novel Anti-Glycan Antibodies for Cancer Therapy

GlycoNex to advance development of novel pro-antibody cancer drugs that enhance tumor suppression while minimizing off-site binding to healthy tissues to improve safety and tolerability….

Amphista Therapeutics Unveils New Differentiated Mechanism of Action for BRD9 Degradation

Amphista Therapeutics Unveils New Differentiated Mechanism of Action for BRD9 Degradation

Amphista’s bifunctional BRD9 degraders selectively induce BRD9 to DCAF16 proximity and serve as molecular glues, leading to strong and rapid degradation of BRD9….

Alvotech & Dr. Reddy’s Enter Commercialization Collaboration 

Alvotech & Dr. Reddy’s Enter Commercialization Collaboration 

Alvotech and Dr. Reddy’s Laboratories SA recently announced the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

 

Synchronizing and controlling API delivery, extrusion-spheronization (E-S) offers pharmaceutical companies a robust technique to manufacture today’s most complex therapeutics. Manufacturing oral solid dose (OSD) APIs into spheres via E-S is not new. What is new is that in the …

WHITEPAPER - A Holistic Approach to Getting the First Batch Right

WHITEPAPER - A Holistic Approach to Getting the First Batch Right

By: Mark Rauckhorst, Director Supply Chain and Project Management, Vetter Development Service USA. Inc.

Clinical trials are high-visibility milestones for investors, as this is often the first major step toward financial return on what has likely been years of investment …

WHITEPAPER - Continuous Flow - An Emerging Alternative

WHITEPAPER - Continuous Flow - An Emerging Alternative

Pharmaceutical companies have traditionally been risk-averse, often adopting safe and well-established processes due to the conservative stance of regulatory agencies on novel methodologies. However, with the increasing complexity of drug molecules and the demand for newer and harsher reaction conditions, …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 5 – Prefilled Syringes
June 12 – Inhalation Delivery